Skip to main content
SpringerLink
Log in

Advances in Studies of Chiglitazar Sodium, a Novel PPAR Pan-Agonist, for the Treatment of Type 2 Diabetes Mellitus

  • Review
  • Published:
Current Medical Science Aims and scope Submit manuscript

Abstract

Chiglitazar sodium is a new peroxisome proliferator-activated receptor (PPAR) pan-agonist with independent intellectual property rights in China. It can treat type 2 diabetes mellitus and regulate metabolism by modestly activating PPARα, PPARγ, and PPARδ to improve insulin sensitivity, regulate blood glucose, and promote fatty acid oxidation and utilization. Chiglitazar sodium has a significant insulin-sensitizing effect and is advantageous in reducing fasting and postprandial blood glucose levels, particularly at the 48 mg dose in patients with concomitant high triglycerides in terms of blood glucose and triglyceride level control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Athyros VG, Doumas M, Imprialos KP, et al. Diabetes and lipid metabolism. Hormones (Athens), 2018,17(1):61–67

    Article  PubMed  Google Scholar 

  2. Javeed N, Matveyenko AV. Circadian Etiology of Type 2 Diabetes Mellitus. Physiology (Bethesda), 2018,33(2):138–150

    CAS  PubMed  Google Scholar 

  3. Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012. N Engl J Med, 2017,376(15):1419–1429

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med, 2006,355(23):2427–2443

    Article  CAS  PubMed  Google Scholar 

  5. Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab, 2014,20 (4):573–591

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Li PP, Shan S, Chen YT, et al. The PPAR alpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. Brit J Pharmacol, 2006,148(5):610–618

    Article  CAS  Google Scholar 

  7. Pan DS, Wang W, Liu NS, et al. Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ. PPAR Res, 2017,2017:4313561

    Article  PubMed  PubMed Central  Google Scholar 

  8. He BK, Ning ZQ, Li ZB, et al. In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist. PPAR Res, 2012,2012:546548

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gross B, Pawlak M, Lefebvre P, et al. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol, 2016,13 (1):36–49

    Article  PubMed  Google Scholar 

  10. Deeks ED. Chiglitazar: First Approval. Drugs, 2022, 82(1):87–92

    Article  CAS  PubMed  Google Scholar 

  11. Haluzík MM, Haluzík M. PPAR-alpha and insulin sensitivity. Physiol Res, 2006,55(2):115–122

    Article  PubMed  Google Scholar 

  12. Cabrero A, Alegret M, Sánchez RM, et al. Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of adipocytes. Diabetes, 2001,50(8):1883–1890

    Article  CAS  Google Scholar 

  13. Chen T, Zhang Y, Liu Y, et al. MiR-27a promotes insulin resistance and mediates glucose metabolism by targeting PPAR-γ-mediated PI3K/AKT signaling. Aging (Albany NY). 2019,11(18):7510–7524

    Article  CAS  PubMed  Google Scholar 

  14. Kamenecka TM, Busby SA, Kumar N, et al. Potent Anti-Diabetic Actions of a Novel Non-Agonist PPARγ Ligand that Blocks Cdk5-Mediated Phosphorylation. In: Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD): National Center for Biotechnology Information (US). 2011

    Google Scholar 

  15. Yessoufou A, Wahli W. Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Med Wkly, 2010,140:w13071

    CAS  PubMed  Google Scholar 

  16. Han L, Shen WJ, Bittner S, et al. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part III: PPAR-β/δ and PPAR-γ. Future Cardiol, 2017,13(3):279–296

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Montaigne D, Butruille L, Staels B. PPAR control of metabolism and cardiovascular functions. Nat Rev Cardiol, 2021,18(12):809–823

    Article  CAS  PubMed  Google Scholar 

  18. Sullivan HJ, Wang X, Nogle S, et al. To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations. PPAR Res, 2020,2020:5314187

    Article  PubMed  PubMed Central  Google Scholar 

  19. Yan LP, Dou GF. In vitro metabolism of chiglitazar. J Chin J Pharmacol Toxicol (Chinese), 2007,21(2):124–130

    CAS  Google Scholar 

  20. Choi JH, Banks AS, Kamenecka TM, et al. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature, 2011,477(7365):477–481

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Xu HR, Zhang JW, Chen WL, et al. Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study. Clin Drug Invest, 2019,39(6):553–563

    Article  CAS  Google Scholar 

  22. Li X, Yu J, Wu M, et al. Pharmacokinetics and Safety of Chiglitazar, a Peroxisome Proliferator-Activated Receptor Pan-Agonist, in Patients < 65 and ≥ 65 Years With Type 2 Diabetes. Clin Pharmacol Drug Dev, 2020,10(7):789–796

    Article  PubMed  Google Scholar 

  23. Yi L, Zhang H, Zhang JW, et al. Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist and Metformin Hydrochloride in Healthy Subjects. Clin Pharmacol Drug Dev, 2019,8(7): 934–941

    Article  CAS  PubMed  Google Scholar 

  24. Lyu X, Gao Y, Zhu L, et al. Efcacy and safety of chiglitazar in type 2 diabetes: a multi-center, randomized, double-blind andparallel group clinical trial. J China Diabetes Mellitus (Chinese), 2019,11(5):334–340

    Google Scholar 

  25. Ji L, Song W, Fang H, et al. Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP). Sci Bull (Beijing), 2021,66(15):1571–1580

    Article  CAS  PubMed  Google Scholar 

  26. Jia W, Ma J, Miao H, et al. Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS). Sci Bull (Beijing), 2021,66(15): 1581–1590

    Article  CAS  PubMed  Google Scholar 

  27. Zhou Y, Wang H, Wang Y, et al. Comparative Evaluation of Chiglitazar and Sitagliptin on the Levels of Retinol-Binding Protein 4 and Its Correlation With Insulin Resistance in Patients With Type 2 Diabetes. Front Endocrinol (Lausanne), 2022,13:801271

    Article  PubMed  Google Scholar 

  28. Wang Y, Li H, Gao H, et al. Effect of chiglitazar and sitagliptin on glucose variations, insulin resistance and inflammatory-related biomarkers in untreated patients with type 2 diabetes. Diabetes Res Clin Pract, 2021,183:109171

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China

    Xin-hui Zhang, Guang-liang Huang, Wen-yan Cui, Qian Sun, Wen-juan He & Xiu-ju Liu

  2. The University of Hong Kong, Hong Kong, 999077, China

    Yun-fei Tian

Authors
  1. Xin-hui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yun-fei Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guang-liang Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wen-yan Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qian Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wen-juan He
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiu-ju Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiu-ju Liu.

Ethics declarations

The author declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Xh., Tian, Yf., Huang, Gl. et al. Advances in Studies of Chiglitazar Sodium, a Novel PPAR Pan-Agonist, for the Treatment of Type 2 Diabetes Mellitus. CURR MED SCI 43, 890–896 (2023). https://doi.org/10.1007/s11596-023-2760-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-023-2760-3

Key words

Search

Navigation